Robust Clinical and Laboratory Response to Hydroxyurea Using Pharmacokinetically Guided Dosing for Young Children with Sickle Cell Anemia

Hydroxyurea is FDA-approved and now increasingly used for children with sickle cell anemia (SCA), but dosing strategies, pharmacokinetic (PK) profiles, and treatment responses for individual patients are highly variable. Typical weight-based dosing with step-wise escalation to maximum tolerated dose...

Popoln opis

Shranjeno v:
Bibliografske podrobnosti
izdano v:Am J Hematol
Main Authors: McGann, Patrick T., Niss, Omar, Dong, Min, Marahatta, Anu, Howard, Thad, Mizuno, Tomoyuki, Lane, Adam, Kalfa, Theodosia A., Malik, Punam, Quinn, Charles T., Ware, Russell E., Vinks, Alexander A.
Format: Artigo
Jezik:Inglês
Izdano: 2019
Teme:
Article
Online dostop:https://ncbi.nlm.nih.gov/pmc/articles/PMC6639795/
https://ncbi.nlm.nih.gov/pubmed/31106898
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1002/ajh.25510
Oznake: Označite
Brez oznak, prvi označite!

Podobne knjige/članki